Status:
COMPLETED
Prevalence and Incidence of Antibodies Against SARS-CoV-2 Among Primary Healthcare Providers in Belgium (COVID-19)
Lead Sponsor:
Universiteit Antwerpen
Collaborating Sponsors:
Sciensano
University of Liege
Conditions:
SARS-CoV-2
COVID-19
Eligibility:
All Genders
Brief Summary
This protocol focuses on the seroprevalence in primary care health care providers (PHCPs) in Belgium. PHCPs manage the vast majority of COVID-19 and other patients and therefore are essential to orga...
Eligibility Criteria
Inclusion
- Any Belgian general practitioner (GP) (including those in professional training) currently working in primary care and any other primary health care providers (PHCPs) from the same GP practice who physically manage (examine, test, treat) patients/clients (frontline PHCP), are able to comply with the study protocol and provided informed consent to participate in the study. Also PHCPs having been diagnosed with COVID-19 are included.
Exclusion
- Staff hired on a temporary (interim) basis will be excluded as follow-up over time will be compromised.
- Administrative staff or technical staff without any contact with patients/clients will also be excluded.
- PHCPs who were not active during the inclusion period will automatically be excluded.
Key Trial Info
Start Date :
November 15 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 31 2023
Estimated Enrollment :
3390 Patients enrolled
Trial Details
Trial ID
NCT04779424
Start Date
November 15 2020
End Date
March 31 2023
Last Update
December 4 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Niels Adriaenssens
Wilrijk, Antwerp, Belgium, 2610